We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

Pulmonary embolism (PE) remains a major contributor to global disease burden. Risk-
adapted treatment and follow-up contributes to a favorable outcome. Age-adjusted cutoff …

Background Low-molecular-weight heparin is the standard treatment for cancer-associated
venous thromboembolism. The role of treatment with direct oral anticoagulant agents is …

The task of developing ESC Guidelines covers not only the integration of the most recent
research, but also the creation of educational tools and implementation programmes for the …

The guideline was drafted by a writing group identified by the Haemostasis and Thrombosis
Task Force of the British Committee for Standards in Haematology (BCSH). All the authors …

PURPOSE Pulmonary embolism is incidentally diagnosed in up to 5% of patients with
cancer on routine imaging scans. The clinical relevance and optimal therapy for incidental …

Essentials We performed a pooled analysis of 926 patients with cancer‐associated
incidental pulmonary embolism (IPE). Vitamin K antagonists (VKA) are associated with a …

In cancer patients, pulmonary embolism (PE) is the second leading cause of death after the
cancer itself, most likely because of difficulties in diagnosing the disease due to its …

Bladder cancer is the most common malignancy of the urinary tract and the ninth most
common malignancy in the world, with an estimated overall global 5-year prevalence of …

Background In recent years, knowledge about cancer associated thrombosis has evolved
considerably. Methods Practical guidelines were drafted on the initiative of the INNOVTE …